Compare · AVDL vs LLY
AVDL vs LLY
Side-by-side comparison of Avadel Pharmaceuticals plc (AVDL) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVDL and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $1.33T.
- LLY has hit the wire 29 times in the past 4 weeks while AVDL has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 15 for AVDL).
- Company
- Avadel Pharmaceuticals plc
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- -
- $1.33T
- 1M return
- -
- +23.23%
- 1Y return
- -
- +55.28%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 29
- Recent ratings
- 15
- 25
Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest AVDL
- SEC Form 15-12G filed by Avadel Pharmaceuticals plc
- Former 10% Owner Weiss Asset Management Lp sold $233,353,092 worth of Ordinary Shares (11,112,052 units at $21.00) (SEC Form 4)
- New insider Weiss Asset Management Lp claimed ownership of 11,112,052 units of Ordinary Shares (SEC Form 3)
- Amendment: SEC Form SCHEDULE 13G/A filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form 4 filed by Chief Operating Officer Rodriguez Susan
- Director Thornton Peter J. returned $2,416,260 worth of Ordinary Shares to the company (115,060 units at $21.00), closing all direct ownership in the company (SEC Form 4)
Latest LLY
- EVP, CS&PO & Pres. LRL Skovronsky Daniel gifted 119 shares, decreasing direct ownership by 0.07% to 159,953 units (SEC Form 4)
- EVP, GC & Secretary Hakim Anat sold $7,012,600 worth of shares (5,000 units at $1,402.52) as part of a pre-agreed trading plan (SEC Form 4)
- EVP & CFO Montarce Lucas converted options into 1,610 shares and covered exercise/tax liability with 678 shares, increasing direct ownership by 6% to 17,191 units (SEC Form 4)
- EVP & Pres., Mfg. Operations Hernandez Edgardo converted options into 2,530 shares and covered exercise/tax liability with 1,123 shares, increasing direct ownership by 3% to 47,490 units (SEC Form 4)
- EVP, Chief People Officer Dozier Eric converted options into 2,300 shares and covered exercise/tax liability with 1,019 shares, increasing direct ownership by 9% to 15,520 units (SEC Form 4)
- EVP & President, Card Met Hlth Custer Kenneth L. converted options into 3,220 shares and covered exercise/tax liability with 1,425 shares, increasing direct ownership by 18% to 11,935 units (SEC Form 4)
- EVP, President LLY Imm Brown Adrienne S converted options into 2,530 shares and covered exercise/tax liability with 1,099 shares, increasing direct ownership by 17% to 9,894 units (SEC Form 4)
- SEC Form 10-Q filed by Eli Lilly and Company
- SEC Form 8-K filed by Eli Lilly and Company
- Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio